LivaNova (NASDAQ:LIVN) Stock Price Expected to Rise, Barclays Analyst Says

LivaNova (NASDAQ:LIVN) had its target price upped by analysts at Barclays from $67.00 to $73.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Barclays‘s target price indicates a potential upside of 3.57% from the stock’s current price.

A number of other research analysts have also recently weighed in on the company. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $66.00 price objective on shares of LivaNova in a research report on Friday, January 9th. KeyCorp initiated coverage on LivaNova in a research report on Friday, December 19th. They set an “overweight” rating and a $81.00 price objective for the company. Robert W. Baird set a $75.00 price target on shares of LivaNova in a research report on Tuesday, December 16th. Needham & Company LLC lifted their price target on shares of LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Mizuho boosted their price target on LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Seven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $74.78.

LivaNova Stock Down 0.7%

LIVN stock traded down $0.51 on Friday, reaching $70.49. 43,323 shares of the company traded hands, compared to its average volume of 722,016. The firm has a fifty day simple moving average of $64.59 and a 200-day simple moving average of $58.90. The company has a market cap of $3.85 billion, a P/E ratio of -15.80 and a beta of 0.97. LivaNova has a one year low of $32.48 and a one year high of $71.92. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.36 and a quick ratio of 1.12.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, February 25th. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.80 by $0.06. The business had revenue of $360.86 million for the quarter, compared to the consensus estimate of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The company’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.81 earnings per share. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Research analysts anticipate that LivaNova will post 2.85 earnings per share for the current year.

Institutional Investors Weigh In On LivaNova

A number of large investors have recently modified their holdings of the business. Hantz Financial Services Inc. lifted its stake in shares of LivaNova by 159.9% in the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after buying an additional 267 shares in the last quarter. State of Wyoming purchased a new position in LivaNova in the 2nd quarter worth approximately $31,000. Quarry LP purchased a new position in LivaNova in the 3rd quarter worth approximately $36,000. EverSource Wealth Advisors LLC boosted its holdings in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after purchasing an additional 639 shares during the last quarter. Finally, Covestor Ltd grew its position in shares of LivaNova by 108.6% in the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after purchasing an additional 392 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.